Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nahdi Medical Company (4164.SR)
Jeddah, Makkah Province, SA
Nahdi Medical Company stands as a prominent pharmaceutical retail chain with operations spanning both the Kingdom of Saudi Arabia and the United Arab Emirates. Its extensive product portfolio encompasses a diverse range of pharmaceutical goods, health and wellness items, maternal and infant care essentials, beauty products, and various fast-moving consumer goods. Beyond retail, Nahdi provides a comprehensive suite of omni-health services, including polyclinics, rapid-care clinics, telemedicine platforms, laboratory facilities, and home healthcare programs. The company is also actively involved in the wholesale and retail distribution of cosmetics, medicines, specialized dietary products, healthy food options, and medical equipment. With approximately 1,151 pharmacies under its management, Nahdi Medical Company was established in 1986 and maintains its headquarters in Jeddah, Saudi Arabia. It operates as a subsidiary under the umbrella of both Alnahdi Holding Company Limited and Saudi Economic and Development Company Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -6.24% | +1.49% | -0.71% | +3.63% | -21.99% | -42.96% | -34.37% | -34.37% | -34.37% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 4 | +1 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+8.1% ★ Q1'26: +6.1% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+1.3% Q1'26: -7.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+5.9% Q1'26: +27.7% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+8.9% ★ Q1'26: +9.8% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+22.5% ★ Q1'26: +34.1% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.0% Q1'26: +0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×1.06× Q1'26: 0.93× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 4 EPS Ana. |
Dec 2027 6 Rev. Ana. 6 EPS Ana. |
Dec 2028 2 Rev. Ana. 3 EPS Ana. |
Dec 2029 5 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
8.62B
est: 8.56B (+0.6%)
|
8.71B
est: 9.11B (-4.3%)
|
9.45B
est: 9.48B (-0.3%)
|
10.21B
est: 10.20B (+0.2%)
|
10.97B
10.84B – 11.11B
+7.6% YoY
|
11.76B
11.50B – 11.95B
+7.2% YoY
|
12.61B
12.38B – 12.78B
+7.2% YoY
|
13.65B
13.41B – 13.85B
+8.3% YoY
|
| EBITDA |
1.59B
est: 1.54B (+2.8%)
|
1.64B
est: 1.63B (+0.8%)
|
1.61B
est: 1.70B (-5.1%)
|
1.69B
est: 1.83B (-7.5%)
|
1.96B
1.94B – 1.99B
+7.6% YoY
|
2.11B
2.06B – 2.14B
+7.2% YoY
|
2.26B
2.22B – 2.29B
+7.2% YoY
|
2.44B
2.40B – 2.48B
+8.3% YoY
|
| EBIT |
988.40M
est: 950.13M (+4.0%)
|
1.03B
est: 971.73M (+5.7%)
|
908.26M
est: 1.01B (-10.2%)
|
907.64M
est: 1.09B (-16.6%)
|
1.17B
1.16B – 1.19B
+7.6% YoY
|
1.25B
1.23B – 1.27B
+7.2% YoY
|
1.34B
1.32B – 1.36B
+7.2% YoY
|
1.46B
1.43B – 1.48B
+8.3% YoY
|
| Net Income |
887.81M
est: 953.34M (-6.9%)
|
892.62M
est: 864.01M (+3.3%)
|
820.72M
est: 833.61M (-1.5%)
|
830.70M
est: 816.58M (+1.7%)
|
852.98M
852.32M – 853.64M
+4.5% YoY
|
926.28M
889.86M – 962.71M
+8.6% YoY
|
1.01B
985.21M – 1.03B
+8.9% YoY
|
1.09B
1.06B – 1.11B
+7.8% YoY
|
| SGA |
421.43M
est: 695.92M (-39.4%)
|
470.28M
est: 449.75M (+4.6%)
|
450.96M
est: 468.11M (-3.7%)
|
492.40M
est: 503.50M (-2.2%)
|
541.80M
535.13M – 548.47M
+7.6% YoY
|
580.78M
567.75M – 590.05M
+7.2% YoY
|
622.50M
611.55M – 631.35M
+7.2% YoY
|
674.24M
662.37M – 683.82M
+8.3% YoY
|
| EPS |
6.83
est: 7.27 (-6.0%)
|
6.87
est: 6.65 (+3.4%)
|
6.31
est: 6.38 (-1.2%)
|
6.39
est: 6.30 (+1.5%)
|
6.56
6.56 – 6.57
+4.2% YoY
|
7.09
6.85 – 7.41
+8.1% YoY
|
7.76
7.58 – 7.90
+9.3% YoY
|
8.36
8.17 – 8.51
+7.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-10 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-03 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-26 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-19 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-15 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI Saudi Arabia ETF KSA | 0.27% | 1.74M | 0.75% |
| 2 | iShares Emerging Markets Equity Factor ETF EMGF | 0.11% | 2.03M | 0.26% |
| 3 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.05% | 188.8K | 0.72% |
| 4 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.05% | 166.7K | 0.74% |
| 5 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.03% | 166.8K | 0.55% |
| 6 | Franklin Emerging Market Core Dividend Tilt Index ETF DIEM | 0.02% | 17.1K | 0.19% |
| 7 | iShares Global Equity Factor ETF GLOF | 0.02% | 38.8K | 0.20% |
| 8 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.02% | 9.6K | 0.15% |
| 9 | Avantis Emerging Markets ex-China Equity ETF AVXC | 0.02% | 64.9K | 0.33% |
| 10 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.01% | 88.2K | 0.44% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yasser Ghulam Bin Abdulaziz Joharji | Chief Executive Officer & Executive Non-Independent Director | 500.0K | male |
| Khalid Tadlaoui | Chief Information Technology Officer | — | male |
| Mohamed Abdullatif | Chief Operation Officer | — | male |
| Mohamed Ramadan | Chief Omni-health Officer | — | — |
| Mohammad Omar Al-Romy | Legal Senior Department Manager & Head of the Legal Department | — | — |
| Mohammed Al-Khubani | Chief Financial Officer | — | male |
| Raed Monagel | Chief Corporate Governance & Business Support Officer | — | male |
| Samer Bokharee | Chief Human Resources Officer | — | male |
| Hossam Khattab | Chief Commercial & Marketing Officer | — | male |
| Zuhair Aytah | Chief Network Development Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4164.SR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
